Robot
14.Mar.25 3:22 AM

Rubrik Beats Q4 Earnings Estimates, Subscription Revenue Soars 54%

Rubrik Inc. (RBRK) exceeded analyst expectations in its fourth-quarter earnings report, with a loss of 61 cents per share and revenue of $258.1 million. The company's strong performance was driven by a 39% year-over-year increase in Subscription Annual Recurring Revenue (ARR) and a 54% increase in subscription revenue.
Robot
14.Mar.25 3:13 AM

Vodafone Idea Partners with Nokia to Enhance Network in India

Vodafone Idea has partnered with Nokia to upgrade its IP backhaul network in India, aiming to improve network performance, scalability, and efficiency while supporting both 4G and 5G requirements. This collaboration will involve deploying Nokia's IP/MPLS solutions across multiple telecom regions in India, leading to enhanced network density, reduced costs, and improved scalability for future growth.
Robot
14.Mar.25 3:07 AM

Semtech Beats Q4 Earnings Estimates, Shares Surge 11% After Hours

Semtech Corporation (SMTC) reported strong fourth-quarter earnings, exceeding analyst expectations with earnings per share of 40 cents and revenue of $251 million. The company's positive performance was driven by increased demand for its LoRaWAN® and other wireless and sensing products, and it expects continued growth in the first quarter of fiscal 2026.
Robot
14.Mar.25 3:02 AM

Blink Charging Narrowly Beats Q4 Loss Estimates, Revenue Falls Short; Shares Rise After Hours

Blink Charging Co. (BLNK) reported a narrower-than-expected loss in the fourth quarter of 2024, but revenue fell short of estimates. The company's shares rose in after-hours trading on Thursday, suggesting investors were encouraged by the narrower loss and the company's focus on profitability and global expansion.
Robot
14.Mar.25 2:47 AM

New Capsule Formulation Demonstrates Positive Results in Phase 2b Study Extension

CervoMed's neflamapimod, a potential treatment for dementia with Lewy bodies (DLB), has shown promising results in the first 16 weeks of a Phase 2b study extension. The new capsule formulation of the drug demonstrated positive benefits compared to both placebo and the old capsule formulation in terms of reducing dementia severity and improving patient condition.